8 children taken to hospitals after seizure-like symptoms at Harvard Square church concert
Crews first received a call about a child suffering from a seizure. When firefighters arrived, the child was sitting outside of the church but was not actively having a seizure, Fire Chief Thomas Cahill said. That quickly escalated into seven other people having seizure-like symptoms, Cahill told WCVB-TV. The department's hazmat team completed a thorough survey of the St. Paul buildings, utilizing several air sampling meters to ensure that no hazardous conditions were present, the news release said. Results were negative, and the buildings were ventilated.
St. Paul's Facebook Page said a French youth choir, the Chœur d'Enfants d'Île-de-France, was offering a free concert at the church on Tuesday night as part of its 2025 US tour. Founded in 1970, the youth choir has traveled extensively and performed with some of the world's top conductors and soloists, St. Paul's said. The concert will feature an exciting mix of sacred and secular repertoire, as well as popular French songs.
Messages seeking comment were emailed to St. Paul's and to the Harvard Catholic Center, the Catholic chaplaincy for Harvard University students and other academic institutions in the area.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Arabiya
an hour ago
- Al Arabiya
Clemson's Dabo Swinney rooting for Hunter Renfrow as he attempts nfl comeback with panthers
Hunter Renfrow remembers being cut by the Las Vegas Raiders on March 13, 2024, and not even caring all that much. He had no desire to play football. Physically, he felt awful. He'd lost 35 pounds, went a week with a 103-degree fever, and was completely zapped of the energy and fire he was once known to bring to the football field. Running routes, catching passes, and being blasted by defensive backs was the last thing on his mind. But after being diagnosed with a severe case of ulcerative colitis–a chronic inflammatory bowel disease that causes inflammation and ulcers in the lining of the large intestine and rectum–the 2021 Pro Bowler is now feeling like himself again. He's trying to make an NFL comeback with the Carolina Panthers, the team he rooted for as a kid growing up in Myrtle Beach, South Carolina. Dabo Swinney, his college coach at Clemson, believes if anyone can make it back, it's Renfrow. 'You're playing football at the highest level, and he just couldn't eat,' Swinney said. 'It affected him, and he was really done (with football). I didn't think he was gonna play again.' Neither did Renfrow. 'I was like, 'I'm never playing a football again,'' Renfroe said. 'Like when you feel like that, you feel like you're letting your teammates down.' Renfrow's problems surfaced late in the 2021 season, in which he caught a career-high 103 passes for 1,038 yards and nine touchdowns. He noticed his energy level had dropped off significantly, and he could never seem to get it all the way back, even after taking a month off to prep for his first Pro Bowl appearance. The Raiders rewarded Renfrow with a two-year, $32 million contract extension that offseason, but he never came close to reaching that level of production again. He caught just 36 passes for 330 yards and two touchdowns in 2022, and 25 passes for 255 yards and no touchdowns in 2023, leading to his release. But after several hospital visits and a referral to a Charlotte-area pediatrician, Renfrow finally received a diagnosis. He began receiving treatment, started a new diet, and saw his appetite return. By September, he'd put back on the 35 pounds he'd lost, and then some. His energy returned. He played pickleball, basketball, and golf, and the competitive juices began to return. As the 2024 NFL season went out without him, Renfrow privately began discussing a possible comeback with Swinney, who has remained a close friend and father figure. 'I was like, 'Hunter, listen, you know you're gonna be 40 one day,'' Swinney said. 'So if you got more left in you ...' In January, Renfrow took Swinney's advice and began to work his way back into football shape. He asked his agent if the Panthers might be interested in giving him a workout. They were, and that ultimately led to a one-year, $1.22 million contract that included a modest $50,000 signing bonus. It was a no-lose proposition for the Panthers. But if Monday is any indication, Renfrow might just be a solid under-the-radar free agent addition for the Panthers. With Swinney observing from the Panthers' sideline as a guest of coach Dave Canales, the 5-foot-10 Renfrow made two impressive catches reminiscent of the player who went from walk-on to catching the game-winning touchdown pass with 1 second remaining in Clemson's dramatic 35-31 win over Alabama in the national championship game in the 2016 season. Renfrow said he feels appreciative as he continues pushing toward something special. While the unimposing Renfrow may look like an ordinary guy off the field, Swinney said that when he puts on the pads, he turns into Superman. 'He catches it. He makes plays,' Swinney said. 'He understands the leverage and influence and route-running and break points and how to set things up and how to play with his hands at full speed. And he's just got elite change of direction. ... But he's a little guy that plays really big and is really crafty. Just his ability to separate and change direction–that's hard to find.' Renfrow is no lock to make the Panthers' roster. The Panthers have upgraded their wide receiver position in recent years, drafting Xavier Legette and Tetairoa McMillan in the first round in 2024 and 2025, respectively. They also have veteran wide receivers Adam Thielen and David Moore, and the team remains high on last year's surprise undrafted rookie standout Jalen Coker. But Canales likes what he's seen so far from Renfrow. 'He looks like the Hunter that I remember,' Canales said. Canales said Renfrow began to show a burst during the teams' OTAs in the spring, and he's been pleased with his development ever since, citing the five-year NFL veteran's knowledge of coverages and leverages and ability to attack defenses. The next month will go a long way toward determining whether Renfrow is able to make it all the way back. Either way, at least he has his health. 'I'm just pulling for him,' Swinney said. 'He's having fun again. He's 29, and so I'm just happy that he's back out here. If he stays healthy, he'll do what Renfrow does. That's just who he is.'
Al Arabiya
3 hours ago
- Al Arabiya
Deion Sanders says he had bladder cancer but will coach Colorado Buffaloes this season
Colorado coach Deion Sanders disclosed Monday that he was diagnosed with an aggressive form of bladder cancer, but after surgery his oncologist considered him cured. Dr. Janet Kukreja, the director of urologic oncology at the CU Cancer Center/UCHealth University of Colorado hospital, said Sanders had his bladder removed as part of the surgical plan. Sanders plans to oversee the Buffaloes this season as he enters his third season at Colorado. Sanders, who turns 58 next month, spoke to the media on the eve of fall camp. He brought his medical team with him to discuss his diagnosis. The charismatic coach returned to campus last week and announced on social media, 'Back and Feeling Great!' He's missed football camps in Boulder this summer amid reports that he's been ill.
Al Arabiya
a day ago
- Al Arabiya
Nih cuts spotlight a hidden crisis facing patients with experimental brain implants
Carol Seeger finally escaped her debilitating depression with an experimental treatment that placed electrodes in her brain and a pacemaker-like device in her chest. But when its batteries stopped working, insurance wouldn't pay to fix the problem, and she sank back into a dangerous darkness. She worried for her life, asking herself: 'Why am I putting myself through this?' Seeger's predicament highlights a growing problem for hundreds of people with experimental neural implants, including those for depression, quadriplegia, and other conditions. Although these patients take big risks to advance science, there's no guarantee that their devices will be maintained – particularly after they finish participating in clinical trials – and no mechanism requiring companies or insurers to do so. A research project led by Gabriel Lázaro-Muñoz, a Harvard University scientist, aimed to change that by creating partnerships between players in the burgeoning implant field to overcome barriers to device access and follow-up care. But the cancellation of hundreds of National Institutes of Health grants by the Trump administration this year left the project in limbo, dimming hope for Seeger and others like her who wonder what will happen to their health and progress. An ethical quagmire – Unlike medications, implanted devices often require parts, maintenance, batteries, and surgeries when changes are needed. Insurance typically covers such expenses for federally approved devices considered medically necessary but not experimental ones. A procedure to replace a battery alone can cost more than $15,000 without insurance, Lázaro-Muñoz said. 'While companies stand to profit from research, there's really nothing that helps ensure that device manufacturers have to provide any of these parts or cover any kind of maintenance,' said Lázaro-Muñoz. Some companies also move on to newer versions of devices or abandon the research altogether, which can leave patients in an uncertain place. Medtronic, the company that made the deep brain stimulation or DBS technology Seeger used, said in a statement that every study is different and that the company puts patient safety first when considering care after studies end. 'People consider various possibilities when they join a clinical trial.' The Food and Drug Administration requires the informed consent process to include a description of reasonably foreseeable risks and discomforts to the participant, a spokesperson said. However, the FDA doesn't require trial plans to include procedures for long-term device follow-up and maintenance, although the spokesperson stated that the agency has requested those in the past. While some informed consent forms say devices will be removed at a study's end, Lázaro-Muñoz said removal is ethically problematic when a device is helping a patient. Plus, he said some trial participants told him and his colleagues that they didn't remember everything discussed during the consent process, partly because they were so focused on getting better. Brandy Ellis, a 49-year-old in Boynton Beach, Florida, said she was desperate for healing when she joined a trial testing the same treatment Seeger got, which delivers an electrical current into the brain to treat severe depression. She was willing to sign whatever forms were necessary to get help after nothing else had worked. 'I was facing death,' she said. 'So it was most definitely consent at the barrel of a gun, which is true for a lot of people who are in a terminal condition.' Patients risk losing a treatment of last resort – Ellis and Seeger, 64, both turned to DBS as a last resort after trying many approved medications and treatments. 'I got in the trial fully expecting it not to work because nothing else had. So I was kind of surprised when it did,' said Ellis, whose device was implanted in 2011 at Emory University in Atlanta. 'I am celebrating every single milestone because I'm like: 'This is all bonus life for me.'' She's now on her third battery. She needed surgery to replace two single-use ones, and the one she has now is rechargeable. She's lucky her insurance has covered the procedures, she said, but she worries it may not in the future. 'I can't count on any coverage because there's nothing that says even though I've had this and it works that it has to be covered under my commercial or any other insurance,' said Ellis, who advocates for other former trial participants. Even if companies still make replacement parts for older devices, she added, availability and accessibility are entirely different things given most people can't afford continued care without insurance coverage. Seeger, whose device was implanted in 2012 at Emory, said she went without a working device for around four months when the insurance coverage her wife's job at Emory provided wouldn't pay for battery replacement surgery. Neither would Medicare, which generally only covers DBS for FDA-approved uses. With her research team at Emory advocating for her, Seeger ultimately got financial help from the hospital's indigent care program and paid a few thousand dollars out of pocket. She now has a rechargeable battery, and the device has been working well. But at any point, she said that could change. Federal cuts stall solutions – Lázaro-Muñoz hoped his work would protect people like Seeger and Ellis. 'We should do whatever we can as a society to be able to help them maintain their health,' he said. Lázaro-Muñoz's project received about $987,800 from the National Institute of Mental Health in the 2023 and 2024 fiscal years and was already underway when he was notified of the NIH funding cut in May. He declined to answer questions about it. Ellis said any delay in addressing the thorny issues around experimental brain devices hurts patients. 'Planning at the beginning of a clinical trial about how to continue treatment and maintain devices,' she said, 'would be much better than depending on the kindness of researchers and the whims of insurers.' 'If this turns off, I get sick again. Like, I'm not cured,' she said. 'This is a treatment that absolutely works but only as long as I've got a working device.'
